



January 2022 | Issue 9

BIOSIG TECHNOLOGIES, INC.

OFFICIAL COMPANY NEWSLETTER

MESSAGE FROM OUR CEO

BY KEN LONDONER, FOUNDER, CHAIRMAN & CEO.
BIOSIG TECHNOLOGIES, INC.

We set the pace for 2022 with a strong program at the 27th International AF Symposium, a world renowned conference highlighting the latest advancements in atrial fibrillation. It was particularly gratifying to participate this year in person, which allowed BioSig to showcase our technology with live demonstrations. It was an honor to have Dr. DJ Lakkireddy, Executive Medical Director and Cardiac Electrophysiologist at Kansas City Heart Rhythm Institute at HCA Midwest Health, share his experience with our PURE EP™ technology during a spotlight session presentation titled: Complex AF Case Study Utilizing a New Standard in Signal Processing. With over 16 years of experience, Dr. Lakkireddy is a leading physician recognized for his clinical expertise and compassionate approach to arrhythmia care. We are grateful for his continued support and partnership.

We exited 2021, having completed over 1800 patient cases with the PURE EP™ System. Since then, I am pleased to report that we have surpassed 2,000 patient procedures that provide us with so much valuable clinical data and physician insights. Building on this progress and our plans for accelerated commercial growth in 2022, we have also added significant talent to our clinical team, including our most recent appointment of Zachary Koch, CCDS, CEPS, as our Clinical Director. A seasoned industry leader with 20 years of experience in clinical strategy and commercial sales at Abbott and St. Jude, we couldn't be more excited to welcome Zach to our team.

*We are also making plans to honor the annual American Heart Month public awareness campaign in February to support those battling cardiovascular disease, a fatal condition accounting for over 630,000 deaths in the US each year.**

We wish everyone a happy and heart-healthy February!

PURE EP™ METRICS THAT MATTER

TOTAL PURE EP™ PATIENT CASES

2,000+

TOTAL PURE EP™ UNITS IN THE FIELD

17

WHAT'S INSIDE THIS ISSUE:

THE 27TH ANNUAL
INTERNATIONAL AF SYMPOSIUM

ZACHARY KOCH, CCDS, CEPS,
JOINS AS CLINICAL DIRECTOR

EXPANDING OUR ROBUST IP
PORTFOLIO

MEDICAL ALLEY & CALIFORNIA
LIFE SCIENCES

WHAT'S TO COME: AMERICAN
HEART MONTH &
BIOELECTRONIC MEDICINE DAY

HONORARY MENTIONS

The 27th Annual International AF Symposium

This past month we attended the 27th Annual International AF Symposium. This intensive, three-day symposium bringing together the world's leading researchers, scientists, and innovators to highlight the latest advances in the field of atrial fibrillation. During the event, our executive, clinical and commercial teams hosted demonstrations of our PURE EP™ System, including some of our latest software and algorithmic features.

Dr. Lakkireddy, Executive Medical Director of Kansas City Heart Rhythm Institute, walked the faculty through his experience with our technology. His presentation, Complex AF Case Study Utilizing a New Standard in Signal Processing, highlighted some of PURE EP™'s key areas of differentiation and shared several case study examples from his lab where information provided by the PURE EP™ System was critical to determining procedural outcomes.

“
[The PURE EP™ System] improves the quality of the signal... decreases the reliance on 3D mapping, and significantly improves procedural time and efficiency.”

~DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute, HCA Midwest Health

AF SYMPOSIUM 2022



COMPLEX AF CASE STUDY UTILIZING
A NEW STANDARD IN SIGNAL
PROCESSING

Dhanunjay Lakkireddy, MD
Executive Medical Director, Kansas City
Heart Rhythm Institute, Overland Park, KS

Watch the Presentation

Zachary Koch, CCDS, CEPS, Joins as Clinical Director

Mr. Koch brings over 20 years of experience in clinical strategy and sales in electrophysiology and cardiovascular devices

We are thrilled to welcome Zachary Koch as our Clinical Director. Zach joins BioSig's leadership following a 16-year tenure at St. Jude Medical and Abbott EP, where he held numerous positions across the company's clinical, sales, training, and commercial teams. He has personally supported over 5,000 cardiac mapping procedures and created and led several advanced training and education initiatives for Abbott and St. Jude Medical. In his most recent role as Manager of Strategic EP Clinical Development, Zach successfully founded and launched the Key Accounts Organization for Abbott EP, leading the business and clinical strategy across nine National Accounts. These efforts generated a 20% increase in EP case volume and revenue for the company.

“
As a dedicated lover of electrophysiology and a long-time mapper, signal quality and interpretation are a critical part of my daily life. The PURE EP System's design and function spoke directly to my desire to better understand the complex nature of electrophysiology. So many difficult cases were extended or unresolved due to a lack of clear and precise signal data. I believe PURE EP is unique because it allows the physician to hear directly from the patient without any outside voices complicating the diagnosis. I could not be more excited to join this team and contribute to the expansion of this amazing technology.”

~Zachary Koch, CCDS, CEOS, Clinical Director, BioSig Technologies, Inc.



Zachary Koch, CCDS, CEPS,
Clinical Director,
BioSig Technologies, Inc.

Learn More About Our Team

Expanding Our Robust IP Portfolio



49

issued or allowed
worldwide patents



A strong intellectual property strategy is critical to the growth of any innovative business. We are thrilled to further expand our robust IP portfolio, which now includes 49 issued or allowed worldwide patents covering the PURE EP™ System.

Our latest patent claims cover computer-implemented methods for filtering noise from an input signal. Generally, some current electrophysiology (EP) recording systems can effectively support the treatment of arrhythmias such as atrial flutter and supraventricular tachycardia, which show up as large-amplitude, low-frequency signals. However, more complex and prevalent arrhythmias, such as atrial fibrillation and ventricular tachycardia, which are characterized by low-amplitude, high-frequency signals, have not found an effective evaluation of all relevant signals.

Our novel PURE EP™ System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal dynamic range. This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution analog-to-digital converter. In addition, the PURE EP™ System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency (RF) signal (e.g., from ablation) noise suppression. There is no need for gain switching in this architecture, and the full range of input signals is digitized with high resolution.

[Learn More About Our Latest Patents](#)

“

We are pleased to announce this newest patent allowance which demonstrates the clinical significance of our PURE EP™ System in filtering noise from complex signals in the EP setting. We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias.”

~Ken Londoner, Founder, Chairman, &
CEO, BioSig Technologies, Inc.



MEDICAL ALLEY ASSOCIATION

We recently accepted an invitation to join the Medical Alley Association (MAA), a health coalition dedicated to supporting global leadership and connectivity across the healthcare industry. Headquartered in Golden Valley, Minnesota, the Medical Alley Association is an international, non-profit advocacy organization dedicated to advancing the global leadership of Minnesota's medical technology innovation and its impact around the globe. Medical Alley Association represents and supports Minnesota's Medical Alley—the world's largest concentration of health technology companies. Home to more than 1,000 healthcare companies, members of the Medical Alley Association span the full scope of the healthcare ecosystem, including Medtronic, Boston Scientific, 3M, UnitedHealth Group, Mayo Clinic, and many more. Due to the association's ongoing support, early-stage healthcare company members have raised more than four million dollars over the last five years.

In 2019, we opened an office in Rochester, Minnesota. It is also where we forged our longstanding strategic partnership with the Mayo Clinic, a mainstay medical institution for Medical Alley and the number one ranked the number one hospital in the world, according to US News & World Report.*

[Learn More About Medical Alley](#)

“

With a growing presence in both Minnesota and California, BioSig is straddling some of the country's largest health technology hubs and economies...



Moving from Minnesota's innovation hub to the exploding life sciences sector in California, we recently joined the California Life Sciences Association (CLSA), the state's largest and most influential life sciences advocacy and business leadership organization.

California's life sciences sector continues to lead the nation in economic growth and innovative activity. Our company was born in Los Angeles, and we are thrilled to contribute to the CLSA mission of improving access to innovative technologies and growing California's life science economy.

[Learn More About CLSA](#)

It is an honor to join our peers in both states and work together on supporting the healthcare innovation that benefits patients globally.”

~Ken Londoner,
Founder, Chairman, & CEO,
BioSig Technologies, Inc.

What's to come...



The Alliance for Advancing Bioelectronic Medicine Launches the First...

Bioelectronic Medicine Day

This past month, the non-profit initiative co-founded by us, the Alliance for Advancing Bioelectronic Medicine (AABM), announced the official launch of the first Bioelectronic Medicine Day, a global health awareness campaign designed to support the efforts and advancements within the field of bioelectronic medicine. The Alliance encourages parties inside and outside the field to join and support the initiative recognizing October 8th, 2022 — the 64th anniversary of the first electronic implantable pacemaker — as the official Bioelectronic Medicine Day.

The Alliance for Advancing Bioelectronic Medicine (AABM) recognizes that stakeholders — companies, research institutes, universities, private investors, public funders, and others — will need to address significant challenges to realize the field's full potential. Bioelectronic Medicine Day aims to increase stakeholder engagement and collaboration and grow public awareness about bioelectronic medicine and its long-term potential.



~**Mario Ottiglio**,
Co-Founder, Alliance for Advancing Bioelectronic Medicine

“

We want this to be the day that the entire bioelectronic medicine community joins together to speak with one voice to raise the profile of this community. We view this initiative as an opportunity for organizations and stakeholders to come together, advocate, learn, and encourage payers, policymakers, and the public to look more seriously into this field.”



~**Natasha Drapeau**,
Co-Founder, Alliance for Advancing Bioelectronic Medicine
Executive Vice President, BioSig Technologies, Inc.

“

Effective collaboration is key to advancing healthcare and bringing innovation to patients. In early 2020, the life science communities came together to find a solution to COVID-19. The prompt roll-out of vaccines would not have been possible without shared learnings and shared objectives. Through collaboration, ideas can lead to new products and improved patient outcomes. We look forward to advancing a new frontier of medicine for the benefit of all stakeholders.”

[Read the Full Announcement](#)

Bioelectronic Medicine Day

OCTOBER 8, 2022

Celebrating the Global Bioelectronic Medicine Community

February 2022, American Heart Month



February is a month very close to BioSig's heart. Recognized across the nation as American Heart Month, February marks a necessary time to reflect on the state of cardiovascular care and support the millions of Americans battling heart disease.

AN ESTIMATED

12.1 MILLION PEOPLE

WILL BE DIAGNOSED WITH AFIB BY 2030*

Mark your calendars and stay tuned for more [#AmericanHeartMonth](#) updates in February!

KUDOS TO OUR CFO!

This month, we would like to thank Steve Chaussy, our Chief Financial Officer and one of the first employees of our company, for his steady financial leadership and expert guidance throughout the years.



ABOUT BIOSIG TECHNOLOGIES, INC.

We are the bioelectronic intelligence company on a mission to preserve the unaltered value of heart signals, gather and provide the real data physicians need to better control procedures today, and predict better treatment pathways for tomorrow. We are showing the way to help improve outcomes for every patient. As innovators in the electrophysiology (EP) space, our primary focus is addressing the unmet needs of the field. The PURE EP™ System is designed to improve the \$4 billion EP market through a powerful combination of hardware and software that makes better decision-making possible.

The PURE EP™ System offers a novel way to acquire and process cardiac signals. These are essential diagnostic signals that deliver high clinical value in all types of cardiac ablations. No other systems or technologies preserve the purity of signals physicians need to deliver better outcomes. PURE EP™ was designed to improve clinical decision-making by providing the full cardiac picture. When it comes to operating on a patient's heart, there is no room for uncertainty.

Visit our website to learn more: www.biosig.com

Contact us: info@biosigtech.com



Showing the Way to Better.

Sources:
*www.cdc.gov/heartdisease/facts.htm
*www.mayoclinic.org/about-mayo-clinic/quality/top-ranked
*www.cdc.gov/heartdisease/atrial_fibrillation.htm